Back to Journals » Clinical Ophthalmology » Volume 5

Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection

Authors Suzuma K, Tsuiki, Matsumoto, Fujikawa, Kitaoka

Published 30 June 2011 Volume 2011:5 Pages 897—900

DOI https://doi.org/10.2147/OPTH.S22843

Review by Single anonymous peer review

Peer reviewer comments 3



Kiyoshi Suzuma, Eiko Tsuiki, Makiko Matsumoto, Azusa Fujikawa, Takashi Kitaoka
Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

Abstract: The F10 is a new commercially available scanning laser confocal ophthalmoscope (SLO) that can perform multiple functions. We determined the usefulness of noninvasive evaluation of proliferative diabetic retinopathy (PDR) pathologies before and after intravitreal injection of bevacizumab (IVB) using the new indirect viewing system of the retro-mode function of the F10 SLO, and compared the images histologically with surgically excised fibrovascular membrane from two cases. In PDR, neovascular vessels in fibrovascular membrane were clearly seen with the retro-mode, even after IVB and without blood flow. The F10 SLO may be useful in evaluating neovascular vessels in fibrovascular membrane in PDR and for determining the precise retinal changes in diabetic retinopathy.

Keywords: bevacizumab, imaging, proliferative diabetic retinopathy, retro-mode, scanning laser ophthalmoscope

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.